Currently amounting to US$XX million, the global cancer diagnostic market is estimated to grow with a compounded annual growth rate (CAGR) of XX% during the forecast period of 2016-2021 to reach a market value of US$XX million by the end of 2021. Emergence of new technologies, such as Biomarkers and Point of care testing, the need to contain increasing healthcare expenditure, and increasing incidences of malignant tumors and cancers are some of the major factors driving this market. However, lack of access to modern diagnostic technologies for developing countries, and expensive diagnostic procedures are hindering the growth for the cancer diagnostic market.
Cancer diagnostic market constitutes of methods and products such as biopsy, next generation sequencing, PCR, flow cytometry, and many more. The concerned market is segmented based on these products and methods. Application segment of the market consists of cancer diagnostic, lung cancer diagnostic, breast cancer diagnostic etc. These two segments defines the overall market value.
The report also covers the regional cancer diagnostic market landscape. The geographical regions are divided as North America, Europe, APAC, Middle East, Latin America, and ROW. The report provides details about the market environment in these regions and various other aspects, which influence the market positively and negatively. Five year forecast of the market based on historical and current status is another vital data offered.
Some of the major players in the global cancer diagnostics market include Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Becton, Dickinson and Company, GE Healthcare, QIAGEN N.V., Abbott Laboratories, Inc., Roche Diagnostics, Siemens Healthcare, Philips Healthcare, and C.R. Bard, Inc.
This report offers comprehensive profiles of these companies consisting of their business strategy for cancer diagnostic, R&D expenditure on cancer, financials, SWOT analysis, products and services, and the insightful company analysis by our analyst.
What this report offers: